ImmunityBio stock soars on pancreatic cancer trial win

ImmunityBio (IBRX) stock rose premarket after initiating a Phase 1 trial combining its drug Anktiva with Bristol Myers Squibb's Abraxane for pancreatic cancer. The pre-surgery combo aims to boost immune responses. Founder Patrick Soon-Shiong believes Abraxane helps 'expose' tumors to support macrophage activity.